

2 December 2024

ASX Announcement

Scientific Advisory Board Change

MELBOURNE Australia, 2 December 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) advises that, owing to work commitments, Dr Leigh Farrell has resigned from his position as a member of the Company's Scientific Advisory Board (SAB).

Dr Farrell has been a valued member of the SAB since prior to Island's initial public offering and has provided significant expertise and guidance to the Company during his tenure.

Island's Managing Director and CEO, Dr David Foster, said: *"I would like to extend my sincere gratitude to Leigh for his immense contribution to Island's scientific strategy and development. His expertise and insights have been invaluable, and we appreciate the time and effort he has dedicated to our SAB. We wish Leigh all the best in his future endeavours and thank him for his commitment to Island."*

The Company will seek to appoint an additional SAB member in due course.

To subscribe to Island's monthly newsletter, [IslandWatch](#), and other forms of email communications, please visit [this page](#) of our website.

Approved for release to the ASX by:

Dr David Foster
CEO and Managing Director
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au



About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.